作者: Paul T. Francis , Sas N. Dijk
DOI: 10.1007/978-1-4615-5405-9_25
关键词:
摘要: The development of rational, neurotransmitter-based, pharmacological treatments for Alzheimer’s disease (AD) is largely based on substantial cholinergic abnormalities. However, it now appears likely that the neocortical deficit in AD can only explain a part entire clinical syndrome and loss glutamatergic cortical pyramidal neurones as important.